American Society of Hematology

Figure 5.

$Two-way sensitivity analyses of the cost of pola-R-CHP and the 5-year PFS of pola-R-CHP. (A) Two-way sensitivity analysis of the 5-year PFS of pola-R-CHP and cost of pola-R-CHP when CAR-T therapy is used in the third-line setting for all patients. In this analysis, we vary the cost of pola-R-CHP and the 5-year PFS of pola-R-CHP simultaneously while keeping other parameters constant. The area shaded red represents the scenarios in which pola-R-CHP is the cost-effective strategy at a WTP of $150 000; the areas shaded blue represent the scenarios in which pola-R-CHP is no longer the cost-effective strategy. (B) Two-way sensitivity analysis of the 5-year PFS of pola-R-CHP and cost of pola-R-CHP when CAR-T therapy is used in the second-line setting for primary refractory/early progression (<12 months). Patients who progress after 12 months receive salvage chemoimmunotherapy as a bridge to auto-SCT. In this analysis, we vary the cost of pola-R-CHP and the 5-year PFS of pola-R-CHP simultaneously while keeping other parameters constant. The area shaded red represents the scenarios in which pola-R-CHP is the cost-effective strategy at a WTP of $150 000; the area shaded blue represents the scenarios in which pola-R-CHP is no longer the cost-effective strategy.$

Two-way sensitivity analyses of the cost of pola-R-CHP and the 5-year PFS of pola-R-CHP. (A) Two-way sensitivity analysis of the 5-year PFS of pola-R-CHP and cost of pola-R-CHP when CAR-T therapy is used in the third-line setting for all patients. In this analysis, we vary the cost of pola-R-CHP and the 5-year PFS of pola-R-CHP simultaneously while keeping other parameters constant. The area shaded red represents the scenarios in which pola-R-CHP is the cost-effective strategy at a WTP of $150 000; the areas shaded blue represent the scenarios in which pola-R-CHP is no longer the cost-effective strategy. (B) Two-way sensitivity analysis of the 5-year PFS of pola-R-CHP and cost of pola-R-CHP when CAR-T therapy is used in the second-line setting for primary refractory/early progression (<12 months). Patients who progress after 12 months receive salvage chemoimmunotherapy as a bridge to auto-SCT. In this analysis, we vary the cost of pola-R-CHP and the 5-year PFS of pola-R-CHP simultaneously while keeping other parameters constant. The area shaded red represents the scenarios in which pola-R-CHP is the cost-effective strategy at a WTP of $150 000; the area shaded blue represents the scenarios in which pola-R-CHP is no longer the cost-effective strategy.

This Feature Is Available To Subscribers Only